These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28443355)

  • 21. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes.
    Davis RE; Correll CU
    Expert Rev Neurother; 2016 Jun; 16(6):601-14. PubMed ID: 27042868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs in development for the treatment of schizophrenia.
    Emsley R
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries.
    Garay RP; Citrome L; Samalin L; Liu CC; Thomsen MS; Correll CU; Hameg A; Llorca PM
    Expert Opin Pharmacother; 2016; 17(7):921-36. PubMed ID: 26831200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.
    Vauquelin G; Bostoen S; Vanderheyden P; Seeman P
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):337-72. PubMed ID: 22331262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The optimal level of dopaminergic neurotransmission].
    de Haan L
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1721-2. PubMed ID: 16114285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress?
    Miyake N; Miyamoto S; Jarskog LF
    Clin Schizophr Relat Psychoses; 2012 Oct; 6(3):122-33. PubMed ID: 23006237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.
    Mallet J; Gorwood P; Le Strat Y; Dubertret C
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):651-664. PubMed ID: 31406978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
    Nakata Y; Kanahara N; Iyo M
    J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational drugs in development for focal segmental glomerulosclerosis.
    Trachtman H
    Expert Opin Investig Drugs; 2017 Aug; 26(8):945-952. PubMed ID: 28707483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
    Lobo MC; Whitehurst TS; Kaar SJ; Howes OD
    Neurosci Biobehav Rev; 2022 Jan; 132():324-361. PubMed ID: 34838528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Strange PG
    Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.